FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579103484> ?p ?o ?g. }

• W2579103484 abstract "Abstract We compared anti-thymocyte globulin (ATG-Fresenius median dose 60 mg/kg: n= 48) with alemtuzumab (Campath-1H 100mg: n=25) in 73 patients with multiple myeloma, who underwent dose-reduced conditioning with melphalan and fludarabine, followed by allogeneic stem cell transplantation from matched (n=63) or mismatched (n=10) unrelated donors. Patients of the ATG group had higher age (median 50 vs 47 years, p=0.05), more prior high-dose chemotherapies (p<0.001), while in the Campath group more bone marrow as stem cell source was used (p<0.001). No primary graft failure occurred in both groups. Patients receiving alemtuzumab had a significant faster engraftment of leukocyte (p=0.03) and of platelets (p=0.02) and a lower incidence of acute GvHD grade II-IV (24 vs 47%, p=0.05). However, after treatment with donor lymphocyte infusion due to persistent disease or mixed hematopoietic chimerism the difference of acute GvHD grade II-IV between alemtuzumab and ATG treated patients did not reach statistical significance (32 vs 47%, p=0.2). No difference in incidence of chronic GvHD was observed (25 vs 33%, p=0.6) More CMV seropositive patients in the alemtuzumab group experienced CMV reactivation (100% vs 47%, p=0.001). The cumulative incidence of treatment related mortality at 2 years for ATG and Campath was 29.3% (CI=17–50%) vs 28.5% (CI=15–54%), p=0.7. No significant difference could be observed in the estimated 2 years OS and PFS between ATG and Campath: 53% (CI:38–75) vs 45% (CI:28–73) and 29% (CI:16–54) and 36% (CI: 20–62), respectively. For PFS, in a multivariate analysis relapse to prior high-dose chemotherapy was the strongest negative factor: HR 2.9, p= 0.001. Including only those patients who did not experienced any relapse at time of allogeneic stem cell transplantation the Campath-group had a 2.5 fold higher risk of progression in comparison to the ATG group, but without reaching statistical significance (HR: 2.5, p=0.15). Ten out of 73 patients had KIR-ligand mismatch in GvH direction. While in patients without KIR-ligand mismatch the cumulative incidence of relapse at two years was 50%, none of the KIR-ligand mismatched patients relapsed so far (p=0.02). The immunosuppressive effect from Campath is stronger than ATG resulting in less acute GvHD, but requires more DLI procedures to control diseases and resulted in a trend to a lower PFS in chemosensitive patients. This preliminary data further implicated a major role of KIR-ligand mismatch transplantation in multiple myeloma" @default.
• W2579103484 created "2017-01-26" @default.
• W2579103484 creator A5001646221 @default.
• W2579103484 creator A5001865369 @default.
• W2579103484 creator A5007828638 @default.
• W2579103484 creator A5014745384 @default.
• W2579103484 creator A5017044459 @default.
• W2579103484 creator A5020201354 @default.
• W2579103484 creator A5020301140 @default.
• W2579103484 creator A5048939350 @default.
• W2579103484 creator A5057074442 @default.
• W2579103484 creator A5058925624 @default.
• W2579103484 creator A5071316542 @default.
• W2579103484 creator A5076651597 @default.
• W2579103484 creator A5082862253 @default.
• W2579103484 creator A5087124135 @default.
• W2579103484 date "2004-11-16" @default.
• W2579103484 modified "2023-09-26" @default.
• W2579103484 title "Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma." @default.
• W2579103484 doi "https://doi.org/10.1182/blood.v104.11.980.980" @default.
• W2579103484 hasPublicationYear "2004" @default.
• W2579103484 type Work @default.
• W2579103484 sameAs 2579103484 @default.
• W2579103484 citedByCount "0" @default.
• W2579103484 crossrefType "journal-article" @default.
• W2579103484 hasAuthorship W2579103484A5001646221 @default.
• W2579103484 hasAuthorship W2579103484A5001865369 @default.
• W2579103484 hasAuthorship W2579103484A5007828638 @default.
• W2579103484 hasAuthorship W2579103484A5014745384 @default.
• W2579103484 hasAuthorship W2579103484A5017044459 @default.
• W2579103484 hasAuthorship W2579103484A5020201354 @default.
• W2579103484 hasAuthorship W2579103484A5020301140 @default.
• W2579103484 hasAuthorship W2579103484A5048939350 @default.
• W2579103484 hasAuthorship W2579103484A5057074442 @default.
• W2579103484 hasAuthorship W2579103484A5058925624 @default.
• W2579103484 hasAuthorship W2579103484A5071316542 @default.
• W2579103484 hasAuthorship W2579103484A5076651597 @default.
• W2579103484 hasAuthorship W2579103484A5082862253 @default.
• W2579103484 hasAuthorship W2579103484A5087124135 @default.
• W2579103484 hasConcept C126322002 @default.
• W2579103484 hasConcept C143998085 @default.
• W2579103484 hasConcept C203014093 @default.
• W2579103484 hasConcept C2776364478 @default.
• W2579103484 hasConcept C2776694085 @default.
• W2579103484 hasConcept C2776755627 @default.
• W2579103484 hasConcept C2777408962 @default.
• W2579103484 hasConcept C2778684742 @default.
• W2579103484 hasConcept C2779015954 @default.
• W2579103484 hasConcept C2779263901 @default.
• W2579103484 hasConcept C2780882860 @default.
• W2579103484 hasConcept C2911091166 @default.
• W2579103484 hasConcept C71924100 @default.
• W2579103484 hasConcept C90924648 @default.
• W2579103484 hasConceptScore W2579103484C126322002 @default.
• W2579103484 hasConceptScore W2579103484C143998085 @default.
• W2579103484 hasConceptScore W2579103484C203014093 @default.
• W2579103484 hasConceptScore W2579103484C2776364478 @default.
• W2579103484 hasConceptScore W2579103484C2776694085 @default.
• W2579103484 hasConceptScore W2579103484C2776755627 @default.
• W2579103484 hasConceptScore W2579103484C2777408962 @default.
• W2579103484 hasConceptScore W2579103484C2778684742 @default.
• W2579103484 hasConceptScore W2579103484C2779015954 @default.
• W2579103484 hasConceptScore W2579103484C2779263901 @default.
• W2579103484 hasConceptScore W2579103484C2780882860 @default.
• W2579103484 hasConceptScore W2579103484C2911091166 @default.
• W2579103484 hasConceptScore W2579103484C71924100 @default.
• W2579103484 hasConceptScore W2579103484C90924648 @default.
• W2579103484 hasLocation W25791034841 @default.
• W2579103484 hasOpenAccess W2579103484 @default.
• W2579103484 hasPrimaryLocation W25791034841 @default.
• W2579103484 hasRelatedWork W1955322177 @default.
• W2579103484 hasRelatedWork W1959298548 @default.
• W2579103484 hasRelatedWork W1972184826 @default.
• W2579103484 hasRelatedWork W2085715737 @default.
• W2579103484 hasRelatedWork W2103059035 @default.
• W2579103484 hasRelatedWork W2307932783 @default.
• W2579103484 hasRelatedWork W2547866394 @default.
• W2579103484 hasRelatedWork W2556457539 @default.
• W2579103484 hasRelatedWork W2592727353 @default.
• W2579103484 hasRelatedWork W2743113491 @default.
• W2579103484 isParatext "false" @default.
• W2579103484 isRetracted "false" @default.
• W2579103484 magId "2579103484" @default.
• W2579103484 workType "article" @default.